The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of ERBB2 activating mutations on enhanced internalization and activity of trastuzumab deruxtecan in HER2-non-amplified metastatic breast cancer.
 
Nicholas Mai
Stock and Other Ownership Interests - Gilead Sciences
Honoraria - IntegrityCE
Research Funding - Merck
Travel, Accommodations, Expenses - MJH Life Sciences
 
Bo Liu
Employment - Lilly
 
Anton Safonov
No Relationships to Disclose
 
Sherry Shen
Honoraria - MJH Life Sciences
Research Funding - Merck (Inst); Sermonix Pharmaceuticals (Inst)
 
Sophia Zelizer
No Relationships to Disclose
 
Charlie White
No Relationships to Disclose
 
Yuan Chen
No Relationships to Disclose
 
Pedram Razavi
Honoraria - Daiichi Sankyo/Astra Zeneca; Pfizer
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Epic Sciences; Guardant Health; Loxo/Lilly; Myriad Genetics; NeoGenomics Laboratories; Novartis; PAIGE.AI; Prelude Therapeutics; SAGA Diagnostics; Tempus
Research Funding - AstraZeneca (Inst); Biovica (Inst); Epic Sciences (Inst); GRAIL (Inst); Guardant Health (Inst); Hologic/Biotheranostics (Inst); Illumina (Inst); Invitae (Inst); Myriad Genetics (Inst); NeoGenomics Laboratories (Inst); Novartis (Inst); Tempus (Inst)
 
Komal Jhaveri
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Genentech; Gilead Sciences; Lilly; Novartis; Pfizer; Sanofi; Scorpion Therapeutics; Seagen
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Context Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); RayzeBio (Inst); Scorpion Therapeutics (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gilead Sciences; Intellisphere; Jounce Therapeutics; Lilly; Pfizer; Taiho Pharmaceutical
 
Shanu Modi
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; DualityBio; Genentech; Gilead Sciences; Pfizer; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; DualityBio; Genentech; Gilead Sciences; GlaxoSmithKline; Lilly; Macrogenics; Pfizer; Puma Biotechnology; Seagen; Zymeworks
Research Funding - AstraZeneca (Inst); BioNTech SE (Inst); BioNTech SE (Inst); D3 Bio (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); DualityBio (Inst); Nuvation Bio (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Sarat Chandarlapaty
Stock and Other Ownership Interests - Totus Medicines
Consulting or Advisory Role - AstraZeneca/MedImmune; Casdin Capital; Daiichi Sankyo; Hexagon; Lilly; Novartis; Prelude Therapeutics; SAGA Diagnostics
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for (1) targeting mutant ER with ER PROTACS and (2) targeting CDK4/6 with CDK4/6 PROTACS (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Joshua Drago
Honoraria - Intellisphere
Consulting or Advisory Role - AmMax Bio; AstraZeneca; Baird Conferences; GenagonTherapeutics; Launchpad Therapeutics; MedaCorp; NuProbe
Research Funding - AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Merck (Inst); Orum Therapeutics (Inst)